Synova Life Sciences, a privately-owned biotechnology company, is dedicated to innovating stem cell treatment through the development of advanced medical devices and methodologies. Founded with the mission to harness the body's natural healing power to address degenerative conditions, Synova focuses on creating solutions that improve the efficiency and effectiveness of stem cell harvesting. Their flagship product, a rapid fat processing system, enhances the quality and quantity of stem cells extracted without using damaging enzymes, thereby ensuring healthier and more viable cells for therapeutic use.

Notable figures affiliated with Synova Life Sciences include key investors and advisors from the biotech and medical device industries, although specific names are not disclosed. The company has achieved significant milestones in developing a processing system that doubles the number of viable cells compared to traditional methods. Synova's impact lies in its potential to revolutionize stem cell therapy by providing a more efficient and less invasive means of cell extraction, promising improved outcomes for patients with degenerative conditions.